A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Conditions: Low Grade Serous Ovarian Cancer
Interventions: Drug: avutometinib; Drug: Defactinib; Drug: Pegylated liposomal doxorubicin; Drug: Paclitaxel; Drug: Topotecan; Drug: Letrozole; Drug: Anastrozole
Sponsors: Verastem, Inc.; GOG Foundation; European Network of Gynaecological Oncological Trial Groups (ENGOT)
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

December 20, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments